大麻精神病 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "大麻精神病" in Japanese language version.

refsWebsite

Global rank Japanese rank

22nih.gov

4^th place

24^th place

16doi.org

2^nd place

6^th place

5worldcat.org

5^th place

19^th place

3who.int

195^th place

376^th place

2druglibrary.org

low place

1mhlw.go.jp

1,656^th place

110^th place

1nii.ac.jp

304^th place

20^th place

1ukdpc.org.uk

low place

1agri-biz.jp

low place

1kenkyuukai.jp

low place

9,745^th place

1cannabist.org

low place

1ndl.go.jp

154^th place

11^th place

1cao.go.jp

3,045^th place

220^th place

1openlibrary.org

325^th place

4,191^st place

1psychiatry.org

low place

1gov.uk

432^nd place

1,191^st place

1psychiatryonline.org

4,032^nd place

6,830^th place

1newscientist.com

774^th place

1,286^th place

agri-biz.jp

赤星栄志「大麻草の品種とTHC（マリファナ成分）」『農業経営者』2013年2月号、2013年1月、48-50頁。

cannabist.org

「ダメ。ゼッタイ。」の大麻に関する見解には根拠がない（大麻取締法変革センター）

cao.go.jp

www8.cao.go.jp

名取はにわ、北沢義博、高橋滋(情報公開・個人情報保護審査会). “「平成17年度覚せい剤等撲滅啓発事業の事業計画書の提出について」等の一部開示決定に関する件（平成19年度（行情）答申第398号）”. 内閣府. 2010年4月11日時点のオリジナルよりアーカイブ。2018年11月4日閲覧。

doi.org

Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D'Souza DC, Howes OD (2020-4). “Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis”. Lancet Psychiatry 7 (4): 344–353. doi:10.1016/S2215-0366(20)30074-2. PMC 7738353. PMID 32197092.
Myran, Daniel T.; Harrison, Lyndsay D.; Pugliese, Michael; Solmi, Marco; Anderson, Kelly K.; Fiedorowicz, Jess G.; Perlman, Christopher M.; Webber, Colleen et al. (2023-09-27). “Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis”. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2023.3582. ISSN 2168-622X.
Iseger, Tabitha A.; Bossong, Matthijs G. (2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophrenia Research 162 (1-3): 153–161. doi:10.1016/j.schres.2015.01.033. ISSN 09209964.
結論部に大麻精神病の研究史がある。Favrat, Bernard; Ménétrey, Annick; Augsburger, Marc; et al (2005). “Two cases of "cannabis acute psychosis" following the administration of oral cannabis”. BMC Psychiatry 5 (1). doi:10.1186/1471-244X-5-17. PMC 1079888. PMID 15804348.
Black, Nicola; Stockings, Emily; Campbell, Gabrielle; Tran, Lucy T.; Zagic, Dino; Hall, Wayne D.; Farrell, Michael; Degenhardt, Louisa (12 2019). “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. The Lancet. Psychiatry 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. ISSN 2215-0374. PMC 6949116. PMID 31672337.
D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005-3). “Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction”. Biol Psychiatry 57 (6): 594–608. doi:10.1016/j.biopsych.2004.12.006. PMID 15780846.
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007-7). “Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review”. Lancet 370 (9584): 319–28. doi:10.1016/S0140-6736(07)61162-3. PMID 17662880.
Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2008-11). “Effects of cannabis use on outcomes of psychotic disorders: systematic review”. Br J Psychiatry 193 (5): 357–63. doi:10.1192/bjp.bp.107.046375. PMID 18978312.
Semple, David M.; McIntosh, Andrew M.; Lawrie, Stephen M. (2016). “Cannabis as a risk factor for psychosis: systematic review”. Journal of Psychopharmacology 19 (2): 187–194. doi:10.1177/0269881105049040. PMID 15871146.
Marconi, Arianna; Di Forti, Marta; Lewis, Cathryn M.; Murray, Robin M.; Vassos, Evangelos (2016-9). “Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis”. Schizophrenia Bulletin 42 (5): 1262–1269. doi:10.1093/schbul/sbw003. PMC 4988731. PMID 26884547.
Farris MS, Shakeel MK, Addington J (2020-5). “Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review”. Soc Psychiatry Psychiatr Epidemiol 55 (5): 527–537. doi:10.1007/s00127-019-01810-x. PMID 31796983.
Murrie, Benjamin; Lappin, Julia; Large, Matthew; Sara, Grant. “Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis”. Schizophrenia Bulletin. doi:10.1093/schbul/sbz102. PMID 31618428. https://doi.org/10.1093/schbul/sbz102.
Hjorthøj, Carsten; Posselt, Christine Merrild; Nordentoft, Merete (2021-07-21). “Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark”. JAMA psychiatry. doi:10.1001/jamapsychiatry.2021.1471. ISSN 2168-6238. PMC 8295899. PMID 34287621.
Livne, Ofir; Shmulewitz, Dvora; Sarvet, Aaron L.; Wall, Melanie M.; Hasin, Deborah S. (2021-10-14). “Association of Cannabis Use–Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001–2002 and 2012–2013”. American Journal of Psychiatry: appi.ajp.2021.21010073. doi:10.1176/appi.ajp.2021.21010073. ISSN 0002-953X.
Isaac M, Isaac M, Holloway F (2005-4). “Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care”. Hum Psychopharmacol 20 (3): 207–10. doi:10.1002/hup.674. PMID 15682431.
Hamilton, Ian; Lloyd, Charlie; Hewitt, Catherine; Godfrey, Christine (2014). “Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: A time series analysis”. International Journal of Drug Policy 25 (1): 151–156. doi:10.1016/j.drugpo.2013.05.016. PMID 23867051.

druglibrary.org

National Commission on Marihuana and Drug Abuse (1972). Marihuana: A Signal of Misunderstanding. New American Librar 別の公開サイト
Advisory Committee on Drug Dependence (1968). Cannabis (Report). 英国内務省.

gov.uk

Advisory Council on the Misuse of Drugs (31 March 2003). The Classification of Cannabis under the Misuse of Drugs Act 1971 (2002) (pdf) (Report). 英国内務省. 2023年11月22日閲覧。

kenkyuukai.jp

cannabis.kenkyuukai.jp

世界保健機関 2018, p. 9. 世界保健機関 (2018). WHO 18年6月専門家ピアレビュー (PDF) (Report). 以上は世界保健機関の報告の翻訳であり以下に掲載：“第40回WHO ECDD会議の結果について”. 日本臨床カンナビノイド学会 (2018年9月3日). 2021年1月17日閲覧。

mhlw.go.jp

世界保健機関 (1997). Program on Substance Abuse : Cannabis: a health perspective and research agenda. WHO/MSA/PSA/97.4 (pdf) (Report). World Health Organization. p. 18. 2014年6月10日閲覧。邦訳:世界保健機関 (1997). 大麻：健康上の観点と研究課題 (pdf) (Report). 厚生労働省. p. 26. 2023年11月22日閲覧。

ndl.go.jp

warp.da.ndl.go.jp

名取はにわ、北沢義博、高橋滋(情報公開・個人情報保護審査会). “「平成17年度覚せい剤等撲滅啓発事業の事業計画書の提出について」等の一部開示決定に関する件（平成19年度（行情）答申第398号）”. 内閣府. 2010年4月11日時点のオリジナルよりアーカイブ。2018年11月4日閲覧。

newscientist.com

Emma Young (2002年11月21日). “Cannabis link to mental illness strengthened”. ニュー・サイエンティスト. 2021年1月23日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D'Souza DC, Howes OD (2020-4). “Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis”. Lancet Psychiatry 7 (4): 344–353. doi:10.1016/S2215-0366(20)30074-2. PMC 7738353. PMID 32197092.
結論部に大麻精神病の研究史がある。Favrat, Bernard; Ménétrey, Annick; Augsburger, Marc; et al (2005). “Two cases of "cannabis acute psychosis" following the administration of oral cannabis”. BMC Psychiatry 5 (1). doi:10.1186/1471-244X-5-17. PMC 1079888. PMID 15804348.
Black, Nicola; Stockings, Emily; Campbell, Gabrielle; Tran, Lucy T.; Zagic, Dino; Hall, Wayne D.; Farrell, Michael; Degenhardt, Louisa (12 2019). “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. The Lancet. Psychiatry 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. ISSN 2215-0374. PMC 6949116. PMID 31672337.
D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005-3). “Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction”. Biol Psychiatry 57 (6): 594–608. doi:10.1016/j.biopsych.2004.12.006. PMID 15780846.
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007-7). “Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review”. Lancet 370 (9584): 319–28. doi:10.1016/S0140-6736(07)61162-3. PMID 17662880.
Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2008-11). “Effects of cannabis use on outcomes of psychotic disorders: systematic review”. Br J Psychiatry 193 (5): 357–63. doi:10.1192/bjp.bp.107.046375. PMID 18978312.
Semple, David M.; McIntosh, Andrew M.; Lawrie, Stephen M. (2016). “Cannabis as a risk factor for psychosis: systematic review”. Journal of Psychopharmacology 19 (2): 187–194. doi:10.1177/0269881105049040. PMID 15871146.
Marconi, Arianna; Di Forti, Marta; Lewis, Cathryn M.; Murray, Robin M.; Vassos, Evangelos (2016-9). “Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis”. Schizophrenia Bulletin 42 (5): 1262–1269. doi:10.1093/schbul/sbw003. PMC 4988731. PMID 26884547.
Farris MS, Shakeel MK, Addington J (2020-5). “Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review”. Soc Psychiatry Psychiatr Epidemiol 55 (5): 527–537. doi:10.1007/s00127-019-01810-x. PMID 31796983.
Murrie, Benjamin; Lappin, Julia; Large, Matthew; Sara, Grant. “Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis”. Schizophrenia Bulletin. doi:10.1093/schbul/sbz102. PMID 31618428. https://doi.org/10.1093/schbul/sbz102.
Hjorthøj, Carsten; Posselt, Christine Merrild; Nordentoft, Merete (2021-07-21). “Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark”. JAMA psychiatry. doi:10.1001/jamapsychiatry.2021.1471. ISSN 2168-6238. PMC 8295899. PMID 34287621.
Verdoux H, Tournier M (2004). “Cannabis use and risk of psychosis: an etiological link?”. Epidemiol Psichiatr Soc 13 (2): 113–9. PMID 15298320.
Isaac M, Isaac M, Holloway F (2005-4). “Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care”. Hum Psychopharmacol 20 (3): 207–10. doi:10.1002/hup.674. PMID 15682431.
Hamilton, Ian; Lloyd, Charlie; Hewitt, Catherine; Godfrey, Christine (2014). “Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: A time series analysis”. International Journal of Drug Policy 25 (1): 151–156. doi:10.1016/j.drugpo.2013.05.016. PMID 23867051.

pmc.ncbi.nlm.nih.gov

Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D'Souza DC, Howes OD (2020-4). “Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis”. Lancet Psychiatry 7 (4): 344–353. doi:10.1016/S2215-0366(20)30074-2. PMC 7738353. PMID 32197092.
結論部に大麻精神病の研究史がある。Favrat, Bernard; Ménétrey, Annick; Augsburger, Marc; et al (2005). “Two cases of "cannabis acute psychosis" following the administration of oral cannabis”. BMC Psychiatry 5 (1). doi:10.1186/1471-244X-5-17. PMC 1079888. PMID 15804348.
Black, Nicola; Stockings, Emily; Campbell, Gabrielle; Tran, Lucy T.; Zagic, Dino; Hall, Wayne D.; Farrell, Michael; Degenhardt, Louisa (12 2019). “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. The Lancet. Psychiatry 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. ISSN 2215-0374. PMC 6949116. PMID 31672337.
Marconi, Arianna; Di Forti, Marta; Lewis, Cathryn M.; Murray, Robin M.; Vassos, Evangelos (2016-9). “Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis”. Schizophrenia Bulletin 42 (5): 1262–1269. doi:10.1093/schbul/sbw003. PMC 4988731. PMID 26884547.
Hjorthøj, Carsten; Posselt, Christine Merrild; Nordentoft, Merete (2021-07-21). “Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark”. JAMA psychiatry. doi:10.1001/jamapsychiatry.2021.1471. ISSN 2168-6238. PMC 8295899. PMID 34287621.

ncbi.nlm.nih.gov

Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D'Souza DC, Howes OD (2020-4). “Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis”. Lancet Psychiatry 7 (4): 344–353. doi:10.1016/S2215-0366(20)30074-2. PMC 7738353. PMID 32197092.
Black, Nicola; Stockings, Emily; Campbell, Gabrielle; Tran, Lucy T.; Zagic, Dino; Hall, Wayne D.; Farrell, Michael; Degenhardt, Louisa (12 2019). “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. The Lancet. Psychiatry 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. ISSN 2215-0374. PMC 6949116. PMID 31672337.
Marconi, Arianna; Di Forti, Marta; Lewis, Cathryn M.; Murray, Robin M.; Vassos, Evangelos (2016-9). “Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis”. Schizophrenia Bulletin 42 (5): 1262–1269. doi:10.1093/schbul/sbw003. PMC 4988731. PMID 26884547.

nii.ac.jp

ci.nii.ac.jp

横山尚洋「大麻(カンナビス)精神病 (薬物依存の臨床<特集>)」『精神医学』第34巻第8号、1992年8月、p839-842、NAID 40002058911。

openlibrary.org

National Commission on Marihuana and Drug Abuse (1972). Marihuana: A Signal of Misunderstanding. New American Librar 別の公開サイト

psychiatry.org

Tauheed Zaman, Richard N. Rosenthal, John A. Renner, Jr., Herbert D. Kleber, Robert Milin (2013). "Position Statement on Marijuana as Medicine" (pdf) (Press release). アメリカ精神医学会. 2016年9月1日閲覧。^{[リンク切れ]}

psychiatryonline.org

ajp.psychiatryonline.org

Livne, Ofir; Shmulewitz, Dvora; Sarvet, Aaron L.; Wall, Melanie M.; Hasin, Deborah S. (2021-10-14). “Association of Cannabis Use–Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001–2002 and 2012–2013”. American Journal of Psychiatry: appi.ajp.2021.21010073. doi:10.1176/appi.ajp.2021.21010073. ISSN 0002-953X.

ukdpc.org.uk

イギリス薬物政策委員会 (2012-10) (pdf). A fresh ApproAch to drugs. the UK Drug Policy Commission. p. 65-66. ISBN 978-1-906246-41-9 2014年9月1日閲覧。

who.int

世界保健機関、(翻訳)融道男、小見山実、大久保善朗、中根允文、岡崎祐士『ICD-10精神および行動の障害:臨床記述と診断ガイドライン』（新訂版）医学書院、2005年。ISBN 978-4-260-00133-5。、世界保健機関 (1992) (pdf). The ICD-10 Classification of Mental and Behavioural Disorders : Clinical descriptions and diagnostic guidelines (blue book). World Health Organization 英語原本では Neurosis and psychosis(p10), Disorder(p11) , F1x.5 Psychotic disorder (pp72-73) の項。
Bertha K. Madras (2015). Update of Cannabis and its medical use (pdf) (Report). World Health Organization. p. 10. 2016年9月1日閲覧。^{[リンク切れ]}

whqlibdoc.who.int

世界保健機関 (1997). Program on Substance Abuse : Cannabis: a health perspective and research agenda. WHO/MSA/PSA/97.4 (pdf) (Report). World Health Organization. p. 18. 2014年6月10日閲覧。邦訳:世界保健機関 (1997). 大麻：健康上の観点と研究課題 (pdf) (Report). 厚生労働省. p. 26. 2023年11月22日閲覧。

worldcat.org

search.worldcat.org

Myran, Daniel T.; Harrison, Lyndsay D.; Pugliese, Michael; Solmi, Marco; Anderson, Kelly K.; Fiedorowicz, Jess G.; Perlman, Christopher M.; Webber, Colleen et al. (2023-09-27). “Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis”. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2023.3582. ISSN 2168-622X.
Iseger, Tabitha A.; Bossong, Matthijs G. (2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophrenia Research 162 (1-3): 153–161. doi:10.1016/j.schres.2015.01.033. ISSN 09209964.
Black, Nicola; Stockings, Emily; Campbell, Gabrielle; Tran, Lucy T.; Zagic, Dino; Hall, Wayne D.; Farrell, Michael; Degenhardt, Louisa (12 2019). “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. The Lancet. Psychiatry 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. ISSN 2215-0374. PMC 6949116. PMID 31672337.
Hjorthøj, Carsten; Posselt, Christine Merrild; Nordentoft, Merete (2021-07-21). “Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark”. JAMA psychiatry. doi:10.1001/jamapsychiatry.2021.1471. ISSN 2168-6238. PMC 8295899. PMID 34287621.
Livne, Ofir; Shmulewitz, Dvora; Sarvet, Aaron L.; Wall, Melanie M.; Hasin, Deborah S. (2021-10-14). “Association of Cannabis Use–Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001–2002 and 2012–2013”. American Journal of Psychiatry: appi.ajp.2021.21010073. doi:10.1176/appi.ajp.2021.21010073. ISSN 0002-953X.